Vimarsana
Biggest News Aggregation in the World

Page 7 - Deep Genomics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Deep Genomics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Deep Genomics Today - Breaking & Trending Today

Hear how Cambrian BioPharma is reinventing drug (and drug company) development - Vimarsana News

Hear how Cambrian BioPharma is reinventing drug (and drug company) development

I'm thrilled to announce this TechCrunch Live event. The startup Cambrian BioPharma is developing a life-changing technology while pioneering a radical approach

Altis Labs closes $7.9 million CAD to evaluate cancer treatments using AI - Vimarsana News

Altis Labs closes $7.9 million CAD to evaluate cancer treatments using AI

Toronto-based Altis Labs, which helps biopharma firms analyze medical imaging and expedite clinical trials with AI, has secured $7.9 million in seed funding.

Hear how Cambrian BioPharma is reinventing drug (and drug company) development - Vimarsana News

Hear how Cambrian BioPharma is reinventing drug (and drug company) development

Join TechCrunch Live on May 3 at 12 pm PDT to hear Maryanna Saenko of Future Ventures and James Peyer speak on the innovative work of Cambrian BioPharma.

Hear how Cambrian BioPharma is reinventing drug (and drug company) development - Vimarsana News

Hear how Cambrian BioPharma is reinventing drug (and drug company) development

Join TechCrunch Live on May 3 at 12 pm PDT to hear Maryanna Saenko of Future Ventures and James Peyer speak on the innovative work of Cambrian BioPharma.

Federal government names six funds to distribute $50 million VCCI life science financing - Vimarsana News

Federal government names six funds to distribute $50 million VCCI life science financing

The federal government has named six funds that will be responsible for doling out the $50 million slotted for the life science stream of the renewed VCCI.